MedTrace Logo

Mechanisms of Refractory Hypertension (Carvedilol)

NCT02357004 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-06-12

No results posted yet for this study

Summary

The purpose of this protocol is test whether patients with hypertension refractory to antihypertensive treatment have evidence of excessive sympathetic (i.e., nervous system) activity.

Conditions

  • Hypertensive

Interventions

DRUG

Carvedilol

CR 40 mg daily in addition to normal BP medications

DRUG

Chlorthalidone

12.5 mg daily in addition to normal BP medications

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • David A. Calhoun, MD · Cardiology Department - University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2020-01-31
Completion
2020-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02357004 on ClinicalTrials.gov